Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2016, vol. 22, issue 1
Subject Area: Medicine
Pages: 1036-1038
DOI: 10.5272/jimab.2016221.1036
Published online: 09 March 2016

J of IMAB 2016 Jan-Mar;22(1):1036-1038
Deyan DavidovCorresponding Autor.
Department of Medical Oncology, UMHAT- Dr. G. Stranski, Medical University, Pleven, Bulgaria.

Objective: The standard treatment for inoperable skin melanoma is chemotherapy. The aim of this study was to explore the efficacy and safety of therapy with dacarbazine in patients with advanced melanoma.
Methods: Twenty- seven consecutive patients with inoperable stage III or IV skin melanoma were treated with chemotherapy. Treatment schedule consists of dacarbazine 150 mg/ m2 days 1- 5 administered every 3- 4 weeks.
Results: Overall response rate was 14,8% with four partial remissions. The main toxicity were neutropenia and vomitus.
Conclusions: These data confirm that advanced skin melanoma is resistant of chemotherapy with dacarbazine.

Key words: Chemotherapy, Skin melanoma, Survival,

- Download FULL TEXT /PDF 492 KB/
Please cite this article in PubMed Style or AMA (American Medical Association) Style:
Davidov D. Our Experience with Dacarbazine in the Treatment of Patients with Inoperable Skin Melanoma. J of IMAB. 2016 Jan-Mar;22(1):1036-1038. DOI:

Correspondence to: Dr Deyan Davidov, Department of Medical Oncology, Medical University, Pleven; 1, "St. Kliment Ohridsky" Str., 5000 Pleven, Bulgaria; E-mail:

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010 Dec;127(12):2893- 2917. [PubMed] [CrossRef]
2. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final Version of 2009 AJCC Melanoma Staging and Classification. J Clin Oncol. 2009 Dec;27(36):6199-206. [PubMed] [CrossRef]
3. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, et al. Meta- analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008 Feb;26(4):527- 534. [PubMed] [CrossRef]
4. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. National Cancer Institute. SEER Cancer Statistics Review, 1975- 2008. [Internet]
5. Agarwala S. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther. 2009 May;9(5):587-595. [PubMed] [CrossRef]
6. Sasse AD, Sasse EC, Clark LG, Ulloa L, Clark OA. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005413. [PubMed] [CrossRef]
7. McClay EF, McClay ME. Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol. 1996 Dec;23(6):744-753. [PubMed]
8. Hansson J. Systemic therapy of malignant melanoma. Med Oncol. 1997 Jun;14(2):73-81. [PubMed] [CrossRef]
9. Khayat D, Coeffic D, Antoine EC. Overview of medical treatments of metastatic malignant melanoma. ASCO Educational Book Spring: 414-427, 2000
10. Bhatia S, Tycodi S, Thompson J. Treatment of Metastatic Melanoma: An Overview.  Oncology (Williston Park). 2009 May;23(6):488- 496. [PubMed].

Received: 30 November 2015
Published online: 09 March 2016

back to Online Journal